BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20127005)

  • 1. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma.
    Gu F; Ma Y; Zhang Z; Zhao J; Kobayashi H; Zhang L; Fu L
    Oncol Rep; 2010 Mar; 23(3):671-6. PubMed ID: 20127005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Notch1 expression and activation to cisplatin-sensitivity of head and neck squamous cell carcinoma.
    Zhang ZP; Sun YL; Fu L; Gu F; Zhang L; Hao XS
    Ai Zheng; 2009 Feb; 28(2):100-3. PubMed ID: 19550121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
    Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
    Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment.
    Zhang Z; Zhou Z; Zhang M; Gross N; Gong L; Zhang S; Lei D; Zeng Q; Luo X; Li G; Li X
    Biomed Pharmacother; 2019 Oct; 118():109306. PubMed ID: 31545250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma.
    Lee SH; Do SI; Lee HJ; Kang HJ; Koo BS; Lim YC
    Lab Invest; 2016 May; 96(5):508-16. PubMed ID: 26927514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
    Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
    Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
    Tuttle TR; Takiar V; Kumar B; Kumar P; Ben-Jonathan N
    Cancer Lett; 2017 Mar; 389():33-40. PubMed ID: 28025101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma.
    Gao J; Zhao S; Halstensen TS
    Oncol Rep; 2016 Jun; 35(6):3265-74. PubMed ID: 27108527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
    Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
    J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
    Chakravarti N; Myers JN; Aggarwal BB
    Int J Cancer; 2006 Sep; 119(6):1268-75. PubMed ID: 16642480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
    Hasegawa Y; Goto M; Hanai N; Ijichi K; Terada A; Hyodo I; Ogawa T; Fukushima M
    Oncology; 2007; 73(1-2):104-11. PubMed ID: 18337622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
    Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
    Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
    Zhao ZL; Zhang L; Huang CF; Ma SR; Bu LL; Liu JF; Yu GT; Liu B; Gutkind JS; Kulkarni AB; Zhang WF; Sun ZJ
    Sci Rep; 2016 Apr; 6():24704. PubMed ID: 27108536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.